Medical Condition

diffuse large b cell lymphoma

Total Trials

20

Recruiting Now

20

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas — each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — diffuse large b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for diffuse large b cell lymphoma?

ClinicalMetric currently tracks 20 actively recruiting clinical trials for diffuse large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for diffuse large b cell lymphoma?

diffuse large b cell lymphoma research spans Phase 1 (9 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a diffuse large b cell lymphoma clinical trial?

Eligibility criteria for diffuse large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

First Affiliated Hospital of Ningbo University 2 trials

Shanghai Exuma Biotechnology Ltd. 1 trial

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 trial

Jonsson Comprehensive Cancer Center 1 trial

Merck Sharp & Dohme LLC 1 trial

diffuse large b cell lymphoma

Frequently Asked Questions — diffuse large b cell lymphoma Clinical Trials

Recruiting Clinical Trials

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?

SynKIR-310 for Relapsed/Refractory B-NHL

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Frontline of ASCT in High-risk DLBCL

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL